Skip to main content

Table 2 Nonparametric univariate analysis of MRSA versus MSSA: duration of MV, inpatient LOS, ICU LOS, and total cost

From: Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia

Dependent variables MRSA – all (n = 59) MSSA – all (n = 95) P value MRSA Survivors (n = 42) MSSA Survivors (n = 61) P value MRSA nonsurvivors (n = 17) MSSA nonsurvivors (n = 34) P value
Total MV (days) 8 (4–20) 8 (3–14) 0.02 12 (3–21) 7 (3–10) 0.006 5 (4–10) 12 (6–15) 0.28
VAP MV (days) 6 (1–16) 6 (1–10) 0.04 9 (1–16) 3 (1–9) 0.03 3 (3–9) 7 (4–12) 0.38
Total inpatient LOS (days) 20 (11–32) 15 (11–23) 0.04 21 (13–32) 15 (10–25) 0.06 12 (7–29) 16 (13–20) 0.27
VAP inpatient LOS (days) 12 (7–23) 13 (8–18) 0.21 16 (9–26) 13 (8–19) 0.16 5 (3–12) 13 (8–17) 0.46
Total ICU (days)a 13 (6–27) 9 (6–16) 0.006 15 (8–29) 7 (4–12) 0.0002 6 (5–12) 13 (9–19) 0.26
VAP ICU (days)a 7 (3–16) 7 (3–12) 0.04 11 (7–20) 6 (3–11) 0.006 4 (3–10) 10 (6–15) 0.14
Total cost (US$) 40,734 (18,347–71,064) 36,523 (15,539–72,080) 0.30 41,968 (24,173–74,249) 34,939 (14,959–75,787) 0.30 31,597 (17,820–62,967) 45,854 (18,958–55,578) 0.49
  1. A total of 154 patients were included in this analysis. Values are expressed as median (interquartile range). aAnalysis for ICU days was conducted on patients (n = 95) from hospitals that collect ICU stay data. ICU, intensive care unit; LOS, length of stay; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus; MV, mechanical ventilation; VAP, ventilator-associated pneumonia.